Remodeling of immunological biomarkers in patients with chronic hepatitis C treated with direct-acting antiviral therapy

Aggeletopoulou, 2017, Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C, World J. Gastroenterol., 23, 4317, 10.3748/wjg.v23.i24.4317 Al-Wabel, 1995, Interleukin-8 and granulocyte-macrophage colony-stimulating factor secretion in hepatocellular carcinoma and viral chronic active hepatitis, Clin. Immunol. Immunopathol., 74, 231, 10.1006/clin.1995.1034 Araújo, 2013, Dual role of IL-12 in the therapeutic efficacy or failure during combined PEG-Interferon-α2A and ribavirin therapy in patients with chronic hepatitis C, Immunol. Lett., 154, 61, 10.1016/j.imlet.2013.07.010 Bataller, 2005, Liver fibrosis, J. Clin. Invest., 115, 209, 10.1172/JCI24282 Brasil, 2019, 68 Cetean, 2015, The importance of the granulocyte-colony stimulating factor in oncology, Clujul Med., 88, 468 Conti, 2016, Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals, J. Hepatol., 65, 727, 10.1016/j.jhep.2016.06.015 Danova, 2020, Recent advances in the management of chemotherapy-induced neutropenia: biosimilar granulocyte colony-stimulating factor use in Italy, Future Med., 16, 891 de Souza-Cruz, 2016, Liver and blood cytokine microenvironment in HCV patients is associated to liver fibrosis score: a proinflammatory cytokine ensemble orchestrated by TNF and tuned by IL-10, BMC Microbiol., 16, 3, 10.1186/s12866-015-0610-6 Debes, 2017, The path to cancer and back: immune modulation during hepatitis C virus infection, progression to fibrosis and cancer, and unexpected roles of new antivirals, Transplantation, 101, 910, 10.1097/TP.0000000000001623 Greten, 2013, Hepatocellular carcinoma from an immunologic perspective, Clin. Canc. Res., 19, 6678, 10.1158/1078-0432.CCR-13-1721 Hatzakis, 2020, Securing sustainable funding for viral hepatitis elimination plans, Liver Int., 40, 260, 10.1111/liv.14282 Imajo, 2016, Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography, Gastroenterology, 150, 626, 10.1053/j.gastro.2015.11.048 Jakobsen, 2017, Direct-acting antivirals for chronic hepatitis C, Cochrane Database Syst. Rev., 6, CD012143 Jittavisutthikul, 2016, Human transbodies to HCV NS3/4A protease inhibit viral replication and restore host innate immunity, Front. Immunol., 7, 318, 10.3389/fimmu.2016.00318 Lauer, 2001, Hepatitis C virus infection, N. Engl. J. Med., 345, 41, 10.1056/NEJM200107053450107 Maia, 2009, Hepatitis C virus screening and clinical monitoring of biomarkers in patients undergoing hemodialysis, J. Med. Virol., 81, 1220, 10.1002/jmv.21521 Mastrangelo, 1999, Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma, Canc. Gene Ther., 6, 409, 10.1038/sj.cgt.7700066 Menezes, 2017, Strategies for serum chemokine/cytokine assessment as biomarkers of therapeutic response in HCV patients as a prototype to monitor immunotherapy of infectious diseases, Antivir. Res., 141, 19, 10.1016/j.antiviral.2017.02.001 Nitta, 2016, Effects of resistance-associated NS5A mutations in hepatitis C virus on viral production and susceptibility to antiviral reagents, Sci. Rep., 6, 34652, 10.1038/srep34652 Osburn, 2013, Anti-inflammatory cytokines, pro-fibrogenic chemokines and persistence of acute HCV infection, J. Viral Hepat., 20, 404, 10.1111/jvh.12052 Pereira, 2019, Immunological dynamics associated with direct-acting antiviral therapies in naive and experimented HCV chronic-infected patients, Mediat. Inflamm., 11 Perz, 2006, The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide, J. Hepatol., 45, 529, 10.1016/j.jhep.2006.05.013 Reig, 2016, Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy, J. Hepatol., 65, 719, 10.1016/j.jhep.2016.04.008 Sasaki, 2018, Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response, World J. Hepatol., 10, 898, 10.4254/wjh.v10.i12.898 Simmonds, 2013, The origin of hepatitis C virus, vol. 369 Sogni, 2016, All-oral direct-acting antiviral regimens in HIV/hepatitis C virus-coinfected patients with cirrhosis are efficient and safe: real-life results from the prospective ANRS CO13-HEPAVIH cohort, Clin. Infect. Dis., 63, 763, 10.1093/cid/ciw379 Tacke, 2007, Up regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course, J. Gastroenterol. Hepatol., 22, 1256, 10.1111/j.1440-1746.2006.04621.x Tarragô, 2014, Combined impact of hepatitis C virus genotype 1 and interleukin-6 and tumor necrosis factor-α polymorphisms on serum levels of pro-inflammatory cytokines in Brazilian HCV-infected patients, Hum. Immunol., 75, 1075, 10.1016/j.humimm.2014.08.198 World Health Organization, 2017 Zingaretti, 2014, Why is it so difficult to develop a hepatitis C virus preventive vaccine?, Clin. Microbiol. Infect., 20, 103, 10.1111/1469-0691.12493